<DOC>
	<DOC>NCT01352793</DOC>
	<brief_summary>A multicenter phase 3 safety trial in which 5,700 subjects will be assigned in a 2:1 ratio to receive 120 Î¼g rLP2086 vaccine in a 0, 2, 6 month schedule or control. The control group will receive HAVRIX vaccine at month 0 and 6 and saline at month 2. All subjects will be followed for 6 months after the last vaccination to assess safety and tolerability.</brief_summary>
	<brief_title>A Global Phase 3 Safety Study of 120 mcg rLP2086 Vaccine in Adolescents and Young Adults Aged 10 to 25 Years</brief_title>
	<detailed_description />
	<mesh_term>Meningitis</mesh_term>
	<mesh_term>Meningitis, Meningococcal</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Healthy subjects aged 10 to 25 years. Previous vaccination with Hepatitis A virus vaccine Previous vaccination with investigational meningococcal B vaccine History of cultureproven N. meningitidis serogroup B disease Any neuroinflammatory or autoimmune condition Any immune defect that would prevent an effective response to the study vaccine</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>25 Years</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>phase 3 safety study</keyword>
	<keyword>5700 healthy subjects</keyword>
	<keyword>3 vaccine doses at month 0</keyword>
	<keyword>2</keyword>
	<keyword>and 6</keyword>
	<keyword>control HAV/saline/HAV</keyword>
</DOC>